/
CBIO
$18.00-$0.56 (-3.02%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$511.8M
28M shares
52-week range
$8.72 – $27.41
50% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
3.84%
Moderate
Price (6 mo)
Loading chart…
Change$-47.25
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $10.2M | $1.2M | $75.0K | $10.0K | $0 | $10.8M |
| Cost of revenue | $275.1K | $899.3K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$275.1K | −$899.3K | $0 | $1.2M | $75.0K | $10.0K | $0 | $10.8M |
| Gross margin | — | — | 0.0% | 100.0% | 100.0% | 100.0% | — | 100.0% |
| R&D | $40.1M | $47.0M | $44.9M | $47.5M | $28.4M | $20.1M | $28.1M | $138.1M |
| Operating income | −$51.5M | −$61.4M | −$51.5M | −$63.4M | −$47.4M | −$39.3M | −$49.9M | −$152.6M |
| EBITDA | −$51.2M | −$57.0M | −$51.2M | −$63.2M | −$47.2M | −$39.1M | −$44.2M | −$149.7M |
| Net income | −$48.3M | −$54.1M | −$51.0M | −$63.4M | −$46.7M | −$36.9M | −$48.5M | −$153.9M |
| Net margin | — | — | -502.1% | -5469.0% | -62251.7% | -368994.2% | — | -1419.6% |
| EPS (diluted) | -1.18 | -1.34 | -1.12 | -1.23 | -0.89 | -0.58 | -1.40 | -14.78 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-3.20 | $-3.27–$-3.06 | 4 |
| 2027 | $6M | $-3.25 | $-3.65–$-2.80 | 3 |
| 2028 | $8M | $-3.46 | $-4.33–$-2.59 | 5 |
| 2029 | $17M | $-3.74 | $-4.96–$-3.53 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$20.86
Price
$18.00
Implied upside
+16%
Peer comparison
Crescent Biopharma, Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
www.crescentbiopharma.com- Employees
- 44
- IPO / List date
- Jun 16, 2025
- HQ
- WALTHAM, MA
Held by traders on TradeandTell
No one on the platform currently holds CBIO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CBIO as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-10-31 | 1-for-15reverse |
| 2006-02-06 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded CBIO yet.
